<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02399566</url>
  </required_header>
  <id_info>
    <org_study_id>CCTEBMTLA-2015</org_study_id>
    <nct_id>NCT02399566</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma</brief_title>
  <official_title>Comparative Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hunan Province Tumor Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hunan Province Tumor Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare effects of erlotinib and pemetrexed as maintenance&#xD;
      therapy for lung adenocarcinoma. Primary Outcome is the progression free survival (PFS).&#xD;
      Based on prediction of different potential benefit groups, this study may help the oncologist&#xD;
      to optimize and improve the maintenance therapy plan for lung adenocarcinoma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">January 2019</completion_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>two years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate (CBR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The adverse reaction</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression (TTP)</measure>
    <time_frame>two years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Lung Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>followed classical chemotherapy for 4 cycles, use Pemetrexed interventional for the maintenance therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Erlotinib, Pemetrexed</intervention_name>
    <description>followed classical chemotherapy for 4 cycles, use Erlotinib orally for the maintenance therapy.</description>
    <arm_group_label>Comparator</arm_group_label>
    <arm_group_label>Experimental</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically diagnosed stage III/IV Lung Adenocarcinoma;&#xD;
&#xD;
          -  Age of 18-75years; Gender Not Required;&#xD;
&#xD;
          -  Received systemic clinical examination, including chest X-ray, abdomen B ultrasound,&#xD;
             head CT scan, radionuclide bone scan;&#xD;
&#xD;
          -  Received cisplatin chemotherapy for 4 cycles before this study, the curative effect of&#xD;
             chemotherapy is SD or above SD (efficacy evaluation time is 21 days, if it is SD, then&#xD;
             the longest diameter of target lesions shall not increase);&#xD;
&#xD;
          -  Adequate hematologic, renal, and hepatic function, Specific index as follows: liver&#xD;
             function: S-Bilirubin ≤1.5 ULN ; Transaminase≤2 ULN. renal function: S-Creatinine ≤1.2&#xD;
             ULN; blood urea nitrogen ≤1.2 ULN . ULN: upper normal limit. Marrow Hemopoietic&#xD;
             Function: WBC≥4.0×10^9/l, ANC≥2.0×10^9/l platelet count ≥100×10^9/l, Hb≥100 g/l;&#xD;
&#xD;
          -  ECOG PS 0-2,Life expectancy ≥ 3 months; endure more than two cycle chemotherapy;&#xD;
&#xD;
          -  The patients have explicit lung tumor lesions and the lesions were measurable;&#xD;
             (According to the standard of RECIST1.1, they should have at least one of accurately&#xD;
             measurable lesions with the largest diameter ≥ 10mm by spiral CT, MRI);&#xD;
&#xD;
          -  No history of serious drug allergy;&#xD;
&#xD;
          -  Informed consent should be obtained before treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Not histologically or cytologically diagnosed as Lung Adenocarcinoma&#xD;
&#xD;
          -  The age of &gt;75 years or &lt;18 years.&#xD;
&#xD;
          -  Major organ dysfunction and Serious Heart Disease (congestive heart-failure,&#xD;
             incontrollable high-risk arrhythmia, unstable angina, alular disease, myocardial&#xD;
             infarct and Resistant hypertension,);&#xD;
&#xD;
          -  Serious complications and investigator consider it is unsuited enrolling;&#xD;
&#xD;
          -  Pregnant or lactating women;&#xD;
&#xD;
          -  Allergic to research drug;&#xD;
&#xD;
          -  Received cisplatin chemotherapy for 4 cycles before this study, the curative effect of&#xD;
             chemotherapy is PD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>JIANHUA CHEN, MD</last_name>
    <phone>0086-731-89762221</phone>
    <email>cjh_1000@163.com</email>
  </overall_contact>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>March 22, 2015</study_first_submitted>
  <study_first_submitted_qc>March 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2015</study_first_posted>
  <last_update_submitted>March 25, 2015</last_update_submitted>
  <last_update_submitted_qc>March 25, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hunan Province Tumor Hospital</investigator_affiliation>
    <investigator_full_name>Jianhua Chen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>erlotinib</keyword>
  <keyword>pemetrexed</keyword>
  <keyword>maintenance therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Adenocarcinoma of Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pemetrexed</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

